NIH R01s: No Longer the Best Science

By Les Costello NIH R01s: No Longer the Best Science Funding preferences penalize senior investigators, lower the quality of science. © DAN PAGE For 60 years, the US National Institutes of Health R01 research grant mechanism has aimed at funding the highest-quality science to address the important contemporary issues. That began to change in 2008, after NIH Director Elias Zerhouni issued the goal to “Fund the best science, by the best scienti

Written byLes Costello
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

For 60 years, the US National Institutes of Health R01 research grant mechanism has aimed at funding the highest-quality science to address the important contemporary issues.

That began to change in 2008, after NIH Director Elias Zerhouni issued the goal to “Fund the best science, by the best scientists…” 1 As a result, new guidelines, requirements, and considerations have been introduced. Unfortunately, these changes are antithetical and counterproductive to achieving Dr. Zerhouni’s stated goal.

A New Paradigm for NIH Grants

Stimulus Application? Not Me

Losing your lab

The new process has transformed the R01 mechanism into a channel that provides funds for the training and development of new and early-stage investigators (ESIs).

New directives require that “NIH will support New Investigator R01 awards at success rates comparable to those for established investigators submitting new R01 applications.” 2 Even recipients of several already-existing NIH training and development grant programs qualify as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies